Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Caroline Brard"'
Publikováno v:
Genetics in Medicine Open, Vol 2, Iss , Pp 101343- (2024)
Externí odkaz:
https://doaj.org/article/61d4dddf7be34f78b878c159d0abdf4c
Publikováno v:
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-17 (2019)
Abstract Background Performing well-powered randomised controlled trials (RCTs) of new treatments for rare diseases is often infeasible. However, with the increasing availability of historical data, incorporating existing information into trials with
Externí odkaz:
https://doaj.org/article/56c7c84340f8470582cb5e739d00ed1d
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Results of PLA, CD8 and PDL1 (MELscore) in all the samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa5d3e7b4d771f42fe8667c88c0ea8d
https://doi.org/10.1158/1078-0432.22482161.v1
https://doi.org/10.1158/1078-0432.22482161.v1
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Purpose:Less than 50% of patients with melanoma respond to anti–programmed cell death protein 1 (anti–PD-1), and this treatment can induce severe toxicity. Predictive markers are thus needed to improve the benefit/risk ratio of immune checkpoint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130342ef5b960dbb0ebd0956b86de8bf
https://doi.org/10.1158/1078-0432.c.6530840
https://doi.org/10.1158/1078-0432.c.6530840
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d847eb45cb025e855425a9ce83ec5e1d
https://doi.org/10.1158/1078-0432.22482167
https://doi.org/10.1158/1078-0432.22482167
Autor:
Caroline Robert, Stéphan Vagner, Jean-Yves Scoazec, Pascale Morel, SuFey Ong, Kristina Sorg, Sarah Warren, Jéremy Lupu, Emilie Routier, Sara Faouzi, Caroline Brard, Séverine Roy, Shensi Shen, Julien Adam, Isabelle Girault
Kaplan Meier representation of the progression-free survival (PFS) and overall survival (OS) for PDL1, CD8, TIS and Melscore variables in all samples (exploratory and validation cohorts) with a recapitulive table of survival medians (NA : Not Availab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eccd81f44e2537fc5aa6d59e7ceb6dd
https://doi.org/10.1158/1078-0432.22482170.v1
https://doi.org/10.1158/1078-0432.22482170.v1
Autor:
Susanne A. Gatz, Anne C. Harttrampf, Caroline Brard, Francisco J. Bautista, Nicolas André, Samuel Abbou, Jonathan Rubino, Windy Rondof, Marc Deloger, Marc Rübsam, Daniel Hübschmann, Lynley V. Marshall, Souad Nebchi, Isabelle Aerts, Estelle Thebaud, Emilie De Carli, Anne-Sophie Defachelles, Xavier Paoletti, Robert Godin, Kowser Miah, Peter G. Mortimer, Gilles Vassal, Birgit Geoerger
Publikováno v:
Cancer Research. 83:CT087-CT087
Background: AcSé-ESMART is a proof-of-concept, phase I/II platform trial designed to explore targeted agents in a molecularly enriched pediatric population. WEE1 plays a role in DNA repair and cell cycle control and is overexpressed in pediatric can
Autor:
Raphael J. Morscher, Pablo Berlanga, Caroline Brard, Ludovic Lacroix, Birgit Geoerger, Nicolas André, Souad Nebchi, Gaëlle Pierron, Nadège Corradini, Gilles Vassal, G Schleiermacher, Lynley V. Marshall, Peter G. Mortimer, Emilie De Carli, Xavier Paoletti, Isabelle Aerts, Jonathan Rubino
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, Elsevier, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
European Journal of Cancer, 2021, 157, pp.268-277. ⟨10.1016/j.ejca.2021.08.010⟩
International audience; Aim: Arms E and F of the AcSé-ESMART phase I/II platform trial aimed to define the recommended dose and preliminary activity of the dual mTORC1/2 inhibitor vistusertib as monotherapy and with topotecan-temozolomide in a molec
Autor:
Sara Faouzi, Caroline Brard, Jeremy Lupu, Isabelle Girault, Séverine Roy, Kristina Sorg, SuFey Ong, Emilie Routier, Shensi Shen, Caroline Robert, Sarah Warren, Pascale Morel, Julien Adam, Stéphan Vagner, Jean-Yves Scoazec
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose:Less than 50% of patients with melanoma respond to anti–programmed cell death protein 1 (anti–PD-1), and this treatment can induce severe toxicity. Predictive markers are thus needed to improve the benefit/risk ratio of immune checkpoint
Autor:
Francisco Bautista, Isabelle Aerts, Jonathan Rubino, Xavier Paoletti, Nicolas André, Stéphane Ducassou, Raphael J. Morscher, Anne-Sophie Defachelles, Souad Nebchi, Caroline Brard, Gilles Vassal, Emilie De Carli, Estelle Thebaud, Keyvan Rezai, Natasha K. A. van Eijkelenburg, Birgit Geoerger, Nadège Corradini
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (32), pp.3546-3560. ⟨10.1200/JCO.21.01152⟩
Journal of Clinical Oncology, 2021, 39 (32), pp.3546-3560. ⟨10.1200/JCO.21.01152⟩
PURPOSE AcSé-ESMART is a proof-of-concept, phase I or II, platform trial, designed to explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to define the recommended phase II dose and activity of the CDK4/6 inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad6c0217a9283f838c29c6673782f74